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Introduction
Actovegin is a biological drug that has been used for the treatment 
of sports muscle injuries. Several in vitro studies have shed light 
on potential mechanisms of action and the drug has consistently 
demonstrated its potential to reduce return to injury time for 
muscle tears in elite athletes. Yet it was banned for a time under the 
International Olympic Committee (IOC) as a blood doping agent, this 
ban was based on presumptuous conclusions and subsequently lited 
ater no indisputable evidence could be provided. his editorial hopes 
to provide readers with some of the key, objective facts relating to 
Actovegin and then based on this, will ofer an opinion on its role in 
sports medicine. We also hope to highlight the importance of evidence-
based medicine, particularly in the volatile ield of Sports Medicine, and 
the need for facts, not iction.
Actovegin
Actovegin (Takeda Pharmaceutical Company Ltd, Osaka, Japan) is 
a biological drug produced from deproteinised haemodialysate of calf 
serum. Its high standard of quality control and long 50-year history of 
clinical evidence have provided much evidence to support its eicacy 
[1]. Functioning in a similar vain to other calf blood derivatives, it can 
be compared to foetal bovine serum (FBS) which is well known for its 
established role in maintaining cell viability in in vitro tissue culture 
methods. hus, Actovegin may be considered as a highly controlled and 
approved form of FBS with an excellent track record for human use in 
the clinical setting.
In Vitro Evidence
he active component and mechanism of Actovegin has yet to be 
identiied, its efects are likely due to a mixture of ingredients instead 
of a single active compound. Study has shown the drug to not contain 
peptide, growth factor or hormone-like substances [2]. Further, in vitro 
evidence suggests that Actovegin promotes oxidative metabolism and 
shits the redox-balance of cells to produce more oxidized substrates, 
possibly protecting against hypoxic cell injury [2]. his mechanism 
can be logically extrapolated to the irst few hours of muscle injury 
where the goal of any therapeutic intervention would be to interrupt 
the process of cell damaging events, and therefore importantly preserve 
cell viability at the injury site. In vitro evidence has also pointed 
towards Actovegin’s protective efect on injured cell types ranging from 
neuroblastoma cells [3], neutrophils [4] and renal cells [5]. It has also 
been postulated that Actovegin could have a beneicial efect as an 
injective therapy for osteoarthritis [6].
One of the properties of Actovegin is to promote oxidation and 
energy production in cell cultures, its eicacy is assumed to beneit 
post-ischemic metabolic events clinically. A recent in vitro study 
has made unsubstantiated, optimistic claims about the potential 
performance enhancing qualities of Actovegin for clinical use [7]. 
Søndergård et al. inlicted cell membrane injuries to the muscle cells 
with a cytotoxic detergent, Saponin then treated the cell culture with 
Actovegin and analysed mitochondrial activity of the cells. hey 
concluded that as the Actovegin groups had higher mitochondrial 
activity, it must be able to enhance sports performance and failed to 
consider the fact that Actovegin may also have membrane stabilizing 
properties which stabilized cells and allowed the mitochondria to 
function normally. As discussed it the previous section, Actovegin 
is a drug that has been proven to have protective efects on ischemic 
cells. herefore, it is important that we highlight here that the study 
by Søndergård et al. should be viewed as an in vitro cell membrane 
injury study and not a performance analysis. Care must be taken when 
extrapolating conclusions from in vitro evidence, as results will not 
necessarily translate. In fact more care must be taken in concluding 
whether or not any substance will improve performance in humans 
from in vitro studies. his misleading conclusion may have contributed 
to the ictitious hype with article exposure and media attention, thus 
having a detrimental efect on science and medical research. 
Legality and Ergogenic Potential
In December, 2000, the IOC banned the use of Actovegin as an 
ergogenic substance ater noting its proliic use at the Sydney Olympic 
Games and that year’s Tour de France [8]. he ban was lited however, 2 
months later ater no indisputable evidence was provided demonstrating 
Actovegin had performance enhancing potential. he current stance 
from World Anti Doping Agency (WADA) is that Actovegin is legal 
under 50 mL every 6 h. However, 50 mL is 25 fold higher than the 
amount injected for a muscle tear and that is without concentrating the 
drug; making these guidelines somewhat ill-informed. Further, neither 
intravenous nor intramuscular injections of Actovegin are prohibited 
in or out of competition according to latest search in Global Drug 
Reference Online, which is approved by UK Anti-Doping (UKAD), the 
Canadian Centre for Ethics in Sport (CCES), the United States Anti-
Doping Agency (USADA) and WADA [9,10].
A study of 567 diabetic patients showed no improvement in muscle 
strength or condition was found ater maximal Actovegin infusion 
for 160 days [11]. Further, Lee et al. performed another, more recent 
blinded, crossover peak aerobic capacity study in healthy human 
participants [12]. Lee et al. provide deinitive clinical evidence that 
Actovegin did not improve aerobic capacity compared to saline control 
in humans. No signiicant diferences were observed in peak values 
for aerobic power. Additionally, values of gross and net eiciency, and 
caloriic energy equivalents associated with VO
2
 were similar. herefore, 
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in brief, results from this study provide deinitive clinical evidence 
that Actovegin in its maximum permitted dose does not improved 
human peak aerobic capacity. hus, showing the claims by Sondergard 
et al. does not extrapolate to a human population. Interestingly, in a 
recent series of studies with human macrophages using RT-PCR and 
low cytometry, they have tentatively demonstrated a possible role of 
Actovegin as an anti-inlammatory agent, which is consistent with the 
inding that Actovegin can reduce the recovery time in mild muscle 
injuries.
Muscle Injuries - Current Strategies and Issues
Muscle injuries are common in sports, recently diferent injection 
treatment options such as growth factors have demonstrated encouraging 
results, however, with their anabolic properties, interventions that 
utilize growth factors, autologous blood or autologous conditioned 
serum are unfeasible therapeutic options for professional athletes, being 
banned by WADA [10]. Interventions such as Platelet Rich Plasma 
(PRP) and Autologous Conditioning Serum (ACS) have become 
popular augmentative therapies in Sports Medicine, being proposed 
to facilitate muscle healing by optimizing provision of growth factors 
from promising animal study [13-15]. However, again these results 
do not necessarily translate to human trial. Reurink et al. in a recent, 
double-blind, randomized placebo controlled trial, showed no clinical 
or statistical diference between PRP and placebo treated groups [15]. 
his study did highlight the heterogeneity in PRP preparation protocol, 
distinct lack of consistency in quality control and thus, variation 
between individual PRP injections. his is an issue we as authors have 
highlighted previously [6]. he information thus provided suggests that 
there is a lack of an efective, legally utilizable option for professional 
athletes to treat acute muscle injuries. It also dictates that the use of 
blood products as biological drugs for muscular injury is nothing new 
and the Actovegin is a logical option.
Clinical Evidence
he use of Actovegin as an intramuscular injection therapy for 
acute muscle tears was irst documented by Pister and Koller [16]. 
hey reported a reduction in recovery time from 8.3 weeks to 5.5 
weeks in treatment groups. However, their partially blinded case 
control study of 103 patients received several criticisms. Patients were 
recruited from diferent levels of sport and thus treatment regime 
and rehabilitation protocols were therefore not standardised. Further, 
Actovegin was mixed with local anaesthetic, which could have altered 
its pharmacodynamic and kinetic properties. Finally, the outcome 
scores were made on subjective observation by patients and clinicians 
with no pre-injury data to compare with.
Since this study there has been limited supporting evidence for its 
role in the treatment of muscle injuries. Lee et al. have published a study 
on the efects of standalone Actovegin therapy, reporting a reduction in 
return to play time in injured, professional footballers of 8 days when 
compared to physiotherapy alone (p=0.033) [17]. his study using 
players from the same elite football club allowed for standardization of 
intervention, physical itness and rehabilitation protocol. 
Conclusion
he evidence provided in this editorial delivers updated evidence 
that hopefully can dispel the shroud of criticism that has surrounded 
Actovegin. he in vitro evidence provides insight into the mechanism 
by which this biological drug is improving cell oxidative metabolism 
and its role in shiting redox balance to maintain cell viability. he 
clinical evidence provided has highlighted the importance of care in 
extrapolating in vitro indings, which do not necessarily extrapolate 
clinically. Further, the clinical evidence has suggested that standalone 
Actovegin therapy is safe and efective to treat muscle injuries in 
elite sports professionals [17]. It is important therefore, particularly 
in a volatile ield such as Sports Medicine, that an evidence based 
medicine approach is taken throughout and treatments are not judged 
on anecdotal and subjective opinion. Current evidence is suggestive 
that Actovegin is a non-ergogenic, safe and potentially beneicial 
biological drug for the treatment of sports related muscle injury in elite 
athletes. Further research will tease out mechanisms and identify active 
ingredients, while clinical trials could conirm eicacy and establish a 
dose-response relationship. We should remain cautious in generating 
facts over anecdotal iction and tailor the use of any intervention to an 
individual athlete’s need above anything else.
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